India Caps Trade Margins at 30% for Non-Scheduled Anti-Cancer Drugs
The Indian government plans to cap trade margins at 30% of the maximum retail price for 110 non-scheduled anti-cancer drugs, including 35 patented medicines. This move aims to reduce excessive mark-ups, potentially lowering prices by up to 70% and saving patients an estimated Rs 2,500 crore annually. The decision follows Supreme Court concerns over large price gaps between retailer prices and MRPs. A committee is finalizing the list, with implementation expected later this month to improve affordability while ensuring drug availability.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 75%, Right 25%). Overall sentiment is positive (69/100). Lens Score 56/100.
Outlets measured: thetelegraph, news18, opindia, moneycontrol, indiatoday, indianexpress, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 2 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (52–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 8 Oct, 09:45 am. Other outlets followed.